Growth Hormone Deficiency Market Research Report - Forecast till 2027

成長ホルモン欠乏症市場:ブランド別情報 (Norditropin, ジェノトロピン, Humatrope, Saizen, Omnitrope), アプリケーション別 (小児成長ホルモン欠乏症, 特発性低身長, 妊娠期間のための小, ターナー症候群, 成人成長ホルモン欠乏症, プラダーウィリー症候群), ルートによって投与(皮下、筋肉内、静脈内)、流通経路別(病院薬局、小売薬局、診療所、電子商取引)および地域(南北アメリカ、ヨーロッパ、アジア太平洋、中東、アフリカ)-2027年までの予測

ID: MRFR/HC/8950-CR | March 2021 | Region: Global | 124 Pages         

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION 14

2.2 SCOPE OF THE STUDY 14

2.3 RESEARCH OBJECTIVE 14

2.4 MARKET STRUCTURE 14

2.5 ASSUMPTIONS & LIMITATIONS 15

3 RESEARCH METHODOLOGY

3.1 DATA MINING 16

3.2 SECONDARY RESEARCH 17

3.3 PRIMARY RESEARCH 17

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 19

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS

4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY 25

4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY 25

4.2.3 GOVERNMENT INITIATIVES FOR GHD 25

4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS 25

4.3 RESTRAINTS 26

4.3.1 HIGH COST OF GHD TREATMENT 26

4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT 26

4.4 OPPORTUNITIES 27

4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS 27

4.5 CLINICAL TRIALS ANALYSIS 27

4.6 MEGATRENDS 31

4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 31

4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS 31

4.6.3 PRODUCTS UNDER DEVELOPMENT 31

4.7 MACROECONOMIC INDICATORS 33

4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES 33

4.9 LONG ACTING GROWTH HORMONES (LAGH) 36

4.9.1 OVERVIEW 36

4.9.2 DEVELOPMENT 36

4.9.3 UPCOMING PRODUCTS 37

4.9.4 TRENDS 38

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS 39

5.1.1 RESEARCH AND DEVELOPMENT 40

5.1.2 MANUFACTURING 40

5.1.3 DISTRIBUTION 40

5.1.4 MARKETING AND SALES 40

5.1.5 POST-SALES MONITORING 40

5.2 PORTER’S FIVE FORCES MODEL 41

5.2.1 THREAT OF NEW ENTRANTS 41

5.2.2 BARGAINING POWER OF SUPPLIERS 41

5.2.3 THREAT OF SUBSTITUTES 42

5.2.4 BARGAINING POWER OF BUYERS 42

5.2.5 RIVALRY 42

5.3 IMPACT OF COVID-19 43

5.3.1 OVERVIEW 43

5.3.2 IMPACT ON SUPPLY CHAIN 43

5.3.3 IMPACT ON PRODUCTION 43

5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2020) 44

6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND

6.1 OVERVIEW 47

6.2 NORDITROPIN 48

6.3 GENOTROPIN 48

6.4 HUMATROPE 49

6.5 SAIZEN 49

6.6 OMNITROPE 50

6.7 OTHERS 50

7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION

7.1 OVERVIEW 51

7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY 52

7.3 IDIOPATHIC SHORT STATURE 53

7.4 SMALL FOR GESTATIONAL AGE 53

7.5 TURNER SYNDROME 54

7.6 ADULT GROWTH HORMONE DEFICIENCY 54

7.7 PRADER-WILLI SYNDROME 55

7.8 OTHERS 55

8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW 56

8.2 SUBCUTANEOUS 57

8.3 INTRAMUSCULAR 58

8.4 INTRAVENOUS 58

9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW 60

9.2 HOSPITAL PHARMACIES 61

9.3 RETAIL PHARMACIES 62

9.4 CLINICS 62

9.5 E-COMMERCE WEBSITES 63

10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION

10.1 OVERVIEW 64

10.2 AMERICAS 65

10.2.1 NORTH AMERICA 68

10.2.1.1 US 71

10.2.1.2 CANADA 73

10.2.2 LATIN AMERICA 74

10.3 EUROPE 77

10.3.1 WESTERN EUROPE 79

10.3.1.1 GERMANY 82

10.3.1.2 FRANCE 84

10.3.1.3 UK 86

10.3.1.4 ITALY 88

10.3.1.5 SPAIN 89

10.3.1.6 REST OF WESTERN EUROPE 91

10.3.2 EASTERN EUROPE 93

10.4 ASIA-PACIFIC 96

10.4.1 JAPAN 98

10.4.2 CHINA 100

10.4.3 INDIA 102

10.4.4 AUSTRALIA 104

10.4.5 SOUTH KOREA 106

10.4.6 REST OF ASIA-PACIFIC 108

10.5 MIDDLE EAST & AFRICA 110

10.5.1 MIDDLE EAST 112

10.5.2 AFRICA 114

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 117

11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2020) 117

11.3 COMPETITIVE BENCHMARKING 119

11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 120

11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 121

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 121

11.6.1 EXPANSION 122

11.6.2 PRODUCT APPROVAL/FDA APPROVAL 122

12 APPENDIX

12.1 REFERENCES 123

12.2 RELATED REPORTS 123

13 LIST OF TABLES

TABLE 9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 19

TABLE 10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR NORDITROPIN, BY REGION, 2020-2027 (USD MILLION) 20

TABLE 11 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR GENOTROPIN, BY REGION, 2020-2027 (USD MILLION) 20

TABLE 12 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HUMATROPE, BY REGION, 2020-2027 (USD MILLION) 21

TABLE 13 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SAIZEN, BY REGION, 2020-2027 (USD MILLION) 21

TABLE 14 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR OMNITROPE, BY REGION, 2020-2027 (USD MILLION) 22

TABLE 15 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 24

TABLE 16 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PAEDIATRIC GROWTH HORMONE DEFICIENCY, BY REGION, 2020-2027 (USD MILLION) 25

TABLE 17 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR IDIOPATHIC SHORT STATURE, BY REGION, 2020-2027 (USD MILLION) 25

TABLE 18 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SMALL FOR GESTATIONAL AGE, BY REGION, 2020-2027 (USD MILLION) 25

TABLE 19 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR TURNER SYNDROME, BY REGION, 2020-2027 (USD MILLION) 26

TABLE 20 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR ADULT GROWTH HORMONE DEFICIENCY, BY REGION, 2020-2027 (USD MILLION) 26

TABLE 21 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PRADER-WILLI SYNDROME, BY REGION, 2020-2027 (USD MILLION) 27

TABLE 22 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 28

TABLE 23 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SUBCUTANEOUS, BY REGION, 2020-2027 (USD MILLION) 29

TABLE 24 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAMUSCULAR, BY REGION, 2020-2027 (USD MILLION) 29

TABLE 25 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAVENOUS, BY REGION, 2020-2027 (USD MILLION) 30

TABLE 26 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 31

TABLE 27 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2027 (USD MILLION) 32

TABLE 28 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2027 (USD MILLION) 32

TABLE 29 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR CLINICS, BY REGION, 2020-2027 (USD MILLION) 33

TABLE 30 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR E-COMMERCE WEBSITES, BY REGION, 2020-2027 (USD MILLION) 33

TABLE 31 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 35

TABLE 32 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 36

TABLE 33 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 36

TABLE 34 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 37

TABLE 35 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 37

TABLE 36 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 38

TABLE 37 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 39

TABLE 38 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 39

TABLE 39 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 39

TABLE 40 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 40

TABLE 41 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 40

TABLE 42 US: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 41

TABLE 43 US: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 41

TABLE 44 US: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 42

TABLE 45 US: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 42

TABLE 46 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 43

TABLE 47 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 43

TABLE 48 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 44

TABLE 49 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 44

TABLE 50 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 45

TABLE 51 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 45

TABLE 52 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 46

TABLE 53 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 46

TABLE 54 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 47

TABLE 55 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 47

TABLE 56 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 48

TABLE 57 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 48

TABLE 58 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 49

TABLE 59 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 50

TABLE 60 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 50

TABLE 61 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 51

TABLE 62 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 51

TABLE 63 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 52

TABLE 64 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 52

TABLE 65 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 52

TABLE 66 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 53

TABLE 67 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 53

TABLE 68 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 54

TABLE 69 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 54

TABLE 70 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 55

TABLE 71 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 55

TABLE 72 UK: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 56

TABLE 73 UK: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 56

TABLE 74 UK: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 57

TABLE 75 UK: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 57

TABLE 76 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 58

TABLE 77 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 58

TABLE 78 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 59

TABLE 79 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 59

TABLE 80 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 59

TABLE 81 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60

TABLE 82 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 61

TABLE 83 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 61

TABLE 84 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 61

TABLE 85 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 62

TABLE 86 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 62

TABLE 87 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 63

TABLE 88 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 63

TABLE 89 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 64

TABLE 90 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 64

TABLE 91 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 65

TABLE 92 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 66

TABLE 93 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 67

TABLE 94 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 67

TABLE 95 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 68

TABLE 96 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 68

TABLE 97 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 68

TABLE 98 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 69

TABLE 99 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 69

TABLE 100 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 70

TABLE 101 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 70

TABLE 102 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 71

TABLE 103 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 71

TABLE 104 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 72

TABLE 105 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 72

TABLE 106 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 73

TABLE 107 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 73

TABLE 108 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 74

TABLE 109 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 74

TABLE 110 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 75

TABLE 111 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 75

TABLE 112 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 75

TABLE 113 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 76

TABLE 114 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 76

TABLE 115 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 77

TABLE 116 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 77

TABLE 117 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 78

TABLE 118 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78

TABLE 119 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 79

TABLE 120 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 79

TABLE 121 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 80

TABLE 122 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 81

TABLE 123 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 81

TABLE 124 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 82

TABLE 125 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 82

TABLE 126 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 83

TABLE 127 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 83

TABLE 128 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 84

TABLE 129 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 84

TABLE 130 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 84

TABLE 131 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 85

TABLE 132 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 85

TABLE 133 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 86

14 LIST OF FIGURES

FIGURE 1 MARKET DYNAMICS: GLOBAL GROWTH HORMONE DEFICIENCY MARKET 12

FIGURE 2 DRIVERS: IMPACT ANALYSIS 14

FIGURE 3 RESTRAINTS: IMPACT ANALYSIS 14

FIGURE 1 ONGOING CLINICAL TRIALS PHASES (%) 18

FIGURE 2 SUPPLY CHAIN ANALYSIS: GLOBAL GROWTH HORMONE DEFICIENCY MARKET 27

FIGURE 3 PORTER’S FIVE FORCES MODEL 29

FIGURE 4 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020 AND 2027 (USD MILLION) 35

FIGURE 5 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 39

FIGURE 6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020 AND 2027 (USD MILLION) 44

FIGURE 7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020 AND 2027 (USD MILLION) 48

FIGURE 8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 52

FIGURE 9 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2020 (%) 53

FIGURE 10 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2020 (%) 56

FIGURE 11 EUROPE: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2020 (%) 65

FIGURE 12 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2020 (%) 67

FIGURE 13 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2020 (%) 84

FIGURE 14 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2020 (%) 98

FIGURE 15 BENCHMARKING OF MAJOR COMPETITORS 107

FIGURE 16 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 108

FIGURE 17 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 109

成長ホルモン欠乏症市場

成長ホルモン欠乏症は、下垂体が人体の成長に影響を与える十分なホルモンの合成を停止した結果です。

セグメンテーション

By Brand Norditropin Genotropin Humatrope Saizen Omnitrope
アプリケーション別 Pediatric Growth Hormone Deficiency Idiopathic Short Stature Small For Gestational Age Turner Syndrome Adult Growth Hormone Deficiency Prader Willi Syndrome
By Route Of Administration Subcutaneous Intramuscular Intravenous
流通チャネル別 Hospital Pharmacies Retail Pharmacies Clinics E Commerce

キープレーヤー

  • Anhui Anke Biotechnology (Group) Co. Ltd.
  • Pfizer Inc.
  • Genetech Inc.
  • Biopartners GmbH
  • Lifetech Labs
  • Zhongshan Hygene Biopharm Co. Ltd.
  • Novo Nordisk A/S
  • Eli Lily and Company
  • Ipsen S.A.

運転手

  • Healthcare expenditure
  • Clinical trials
  • Safety and efficacy of GHD
  • Changing lifestyle
Speak to Analyst Request a Free Sample

成長ホルモン欠乏症市場の概要


成長ホルモン欠乏症市場は、2020年から2027年の進行中の予測期間中に、4.2%の世界的なCAGRで上昇すると予想されています。このような成長率で予想される成長により、市場は5,24330万米ドル相当の最終市場価値に達すると予想されます。成長ホルモン欠乏症は、下垂体が人体の成長に影響を与える十分なホルモンの合成を停止した結果です。


Covid 19成長ホルモン欠乏症市場の分析


新しいコロナウイルスは、さまざまな種類の市場、プレーヤー、および関連する製造および生産ユニットに膨大な数の課題と制約を生み出すことに成功しています。世界市場の製品とサービスの大幅な減少は、成長ホルモン欠乏症市場の収益の達成可能な数字に影響を与えました。また、コロナウイルス病は、免疫系を含む人々の健康を悪化させています。


したがって、市場のプレーヤーがコロナウイルスによってもたらされた悪影響を乗り越えるのを助けるために、政府は研究開発活動を支援するための資金を増やしています。また、著名な市場プレーヤーは、2021年から2028年の予測期間中にその可能性を高めるのに役立つさまざまな製品を開発および発売しています。


成長ホルモン欠乏症グローバル市場、ブランド別、2019(%)


Growth Hormone Deficiency Market


ソース:MRFR 分析


マーケットダイナミクス


ドライバー


世界の成長ホルモン欠乏症市場が優れたCAGRで成長し、2021年から2028年にかけて途方もない市場収益を達成するのを助ける上で優れた役割を果たす主な要因の1つは、成長ホルモン欠乏症が増加し、続いて老化を制御するためのホルモン使用量。また、グローバル市場運営の拡大中に神経精神医学的症例を増やすのに役立つ治療手順に関する意識の程度が大幅に高まっています。新しい治療法の素晴らしい導入と頑丈なパイプラインの構築があり、その結果、成長ホルモン欠乏症市場が予測期間中に大きな速度で推進するのに役立つ研究開発投資と活動が確実に急増しています。


拘束


しかし、世界市場は高い治療費に関連しており、2028年に終了する予測期間中に成長ホルモン欠乏症市場に多くの可能性のある制約を引き起こすさまざまな製薬会社の医薬品生産性の変動の本拠地でもあります。また、市場の製品には、体液貯留、関節痛、筋肉痛などの多くの副作用があります。ホルモンの合成成長は、市場予測に基づいて成長ホルモン欠乏症市場の成長を妨げています.


テクノロジー分析


北米の米国市場の一部である米国小児科学会が発表したデータに基づくと、成長の欠乏は平均して3,000人に1人から10,000人に1人の子供に影響を与えます。市場の製品とサービスは、アンチエイジング治療として作用し、その後にパフォーマンスを向上させるアナボリック薬として作用するボディビルダーやアスリートによって広く使用されています。


研究目標



  • 成長ドライバーや機会などの利用可能なダイナミクスと、予測における市場の成長を妨げる可能性のある制約の可用性に基づいて、市場の成長の可能性を調査することピリオド。

  • 市場の範囲を拡大するのに役立つ市場細分化を深く理解し、予測期間中の市場の収益の可能性を理解すること。

  • グローバルシナリオの競争力の上昇をもたらしている要因を分析し、続いて市場プレーヤーが地域および国際市場で成長するのを助ける最近の進展を分析すること。


市場細分化


成長ホルモン欠乏症市場は、主要なブランド、アプリケーション、投与経路、流通チャネル、および地域に基づいて世界中に分割されています。


主要ブランドに基づく



  • 市場は、オムニトロープ、サイゼン、ヒューマトロープ、ジェノトロピン、ノルディトロピンなどの主要ブランドに基づいて世界中で分割されています。最大の市場シェアは2017年にNorditropinによって保持されています。


アプリケーションに基づく


市場は、プラダー・ウィリ症候群、ターナー症候群、妊娠期間が小さい、特発性低身長、成長ホルモン欠乏症などへの用途に基づいて、世界中で分割されています。世界市場で最大の市場シェアは、成長ホルモン欠乏症の適用タイプによって保持されています。


管理ルートに基づく


市場は、経口、静脈内、筋肉内、および皮下の投与経路に基づいて世界中で分割されています。


流通チャネルに基づく


市場は、流通チャネルに基づいて、EコマースWebサイト、クリニック、小売薬局、病院薬局に世界中で分割されています。


地域に基づく


市場は、地域に基づいてグローバル市場で北米地域、アジア太平洋地域、ヨーロッパ地域、ラテンアメリカ地域、および中東およびアフリカ地域に分割されています。


西ヨーロッパの成長ホルモン欠乏症の市場シェア、国別、2019(%)


Growth Hormone Deficiency Market


ソース:MRFR 分析


地域分析


成長ホルモン欠乏症市場は、この地域に基づいて、北米地域、アジア太平洋地域、ヨーロッパ地域、ラテンアメリカ地域、中東およびアフリカ地域に分かれています。世界市場で最大の市場シェアは、認識レベルの向上と相まって、償還政策の強化と政府によるイニシアチブがこの地域の市場需要を促進するため、北米地域によって保持されています。さらに、大手製薬会社の存在も市場の需要を牽引しています。


第2に大きい市場



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 5,243.3 Million
  CAGR   4.20%
  Base Year   2020
  Forecast Period   2027
  Historical Data   2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors and Trends
  Segments Covered   Brand, Application, Distribution Channel, and Route of Administration
  Geographies Covered   North America, Europe, Asia-Pacific and Rest of the World (RoW)
  Key Vendors   Novo Nordisk A/S, Eli Lily and Company, Novartis AG, Merck KGaA, and Pfizer
  Key Market Opportunities   hormone products
  Key Market Drivers

  • Healthcare expenditure
  • Clinical trials
  • Safety and efficacy of GHD
  • Changing lifestyle


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Growth Hormone Deficiency Market is projected to grow at a 4.20% CAGR between 2020-2027.

    Growth Hormone Deficiency Market predicted to touch USD 5,243.3Mn by 2027.

    Increasing number of individuals suffering from (GHD)are adding market growth.

    High cost of treatment and increasing counterfeit products may limit market growth.

    The Application included in Growth Hormone Deficiency market are Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small For Gestational Age, Turner Syndrome, Adult Growth Hormone Deficiency, Prader Willi Syndrome.